Abstract: Disclosed is a method of producing a vaccine composition against enteric infection caused by enterotoxigenic E. coli bacteria in humans. E. coli strains selected from different known strains each having the ability of expressing a certain type of colonization factor antigens are grown in a liquid culture medium. Finally formalin-killed E. coli strain having substantially preserved antigenic and hemagglutinating properties of said certain type of colonization factor antigens, is mixed with a pharmaceutically acceptable excipient and/or diluent. Further disclosed is a method of preventing an enteric infection caused by enterotoxigenic E. coli bacteria in humans, whereby a vaccine composition comprising inactivated E. coli strain is administered to a human being for the prevention of said infection.

Abstract: The present invention relates to recombinant polypeptides which constitute Helicobacter pylori surface-exposed antigens with an approximate molecular weight of 29 kDa. The invention furthermore provides nucleic acid molecules coding for the said polypeptides, as well as vectors and host cells comprising such nucleic acid molecules. The said recombinant polypeptides are useful for the diagnosis of H. pylori infections and for the manufacture of vaccine compositions which will elicit a protective immune response against such infections, said vaccine compositions being suitable for both therapeutic and prophylactic use.

Abstract: The present invention relates to a vaccine composition for inducing a protective immune response to Helicobacter pylori infection, said composition comprising an immunogenically effective amount of a polypeptide comprising at least one Helicobacter pylori flagellin polypeptide, optionally together with a pharmaceutically acceptable carrier or diluent.

Abstract: The present invention relates to recombinant polypeptides which constitute Helicobacter pylori surface-exposed antigens with an approximate molecular weight of 29 kDa. The invention furthermore provides nucleic acid molecules coding for the said polypeptides, as well as vectors and host cells comprising such nucleic acid molecules. The said recombinant polypeptides are useful for the diagnosis of H. pylori infections and for the manufacture of vaccine compositions which will elicit a protective immune response against such infections, said vaccine compositions being suitable for both therapeutic and prophylactic use.